Navy SEAL's trial for war crimes begins in San Diego
By Mike Blake SAN DIEGO (Reuters) - Jury selection began on Monday in the trial of a U.S.
By Mike Blake
SAN DIEGO (Reuters) - Jury selection began on Monday in the trial of a U.S. Navy SEAL platoon leader court-martialed on charges of murdering a wounded Iraqi prisoner and shooting unarmed civilians, a war crimes case that has drawn the attention of U.S. President Donald Trump.
Special Operations Chief Edward Gallagher, a career combat veteran, walked into a military courtroom at the U.S. Naval Base in San Diego wearing a Navy white uniform adorned with medals. He has denied all the charges but could face life in prison if convicted in the trial arising from his 2017 deployment to Mosul, Iraq.
Gallagher, 39, is charged with murdering a wounded, helpless Islamic State fighter in his custody by stabbing him in the neck, and with attempted murder in the wounding of two civilians - a schoolgirl and an elderly man - shot from a sniper's perch in Iraq.
He maintains that fellow SEAL team members in his platoon, who turned him in and are testifying against him under grants of immunity, are disgruntled subordinates who fabricated allegations to force him from command.
Lawyers for the defense and prosecution will be selecting between 5 and 15 jurors from a pool, half of whom are officers and the other half enlisted men, Brian O’Rourke, Navy spokesman for U.S. Naval Base San Diego, told reporters on Monday.
Empanelling the jury is expected to take one or two days and the proceedings in a military courthouse at the San Diego base are due to last three weeks.
The prosecution's case rests crucially on the SEAL team members' testimony as there are no bodies or crime scenes from the Iraqi war zone. Names and other details about the alleged crimes were not disclosed.
The opening of the trial was postponed several times by a lengthy round of proceedings to deal with defense allegations of prosecutorial misconduct.
Gallagher's lawyers sought dismissal of the charges after learning that Navy prosecutors had electronically tracked email communications of defense lawyers without a warrant, ostensibly to pinpoint the source of material leaked from sealed case files.
The presiding judge, a Navy captain, ultimately removed the lead prosecutor from the case and freed Gallagher from pre-trial confinement.
The judge also granted defense lawyers a potentially valuable edge in jury selection - the right to reject, with no reason given, two more potential jurors than they otherwise could exclude through the use of a peremptory challenge.
Before he was released from custody late last month, Gallagher had been ordered restricted to base at the nearby Naval Medical Center San Diego.
Trump said last month that he is considering pardons for a number of military service members accused of war crimes, and Gallagher's case was believed to be one of those under review.
The prospect of presidential clemency seemed heightened by last month's appointment to Gallagher's defense team of Marc Mukasey, one of Trump's personal lawyers. Gallagher's lead civilian attorney, Timothy Parlatore, has said his client has not sought a pardon.
(Additional reporting by Marty Graham in San Diego; Writing and additional reporting by Steve Gorman; Editing by Bill Tarrant and Phil Berlowitz)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment
SHANGHAI (Reuters) - China banned pork imports from Germany on Saturday after it confirmed its first case of African swine fever last week, in a move set to hit German producers and push up global prices as China's meat supplies tighten. China's ban on imports from its third largest supplier comes as the world's top meat buyer deals with an unprecedented pork shortage after its own epidemic of the deadly hog disease. The ban on Germany, which has supplied about 14% of China's pork imports so far this year, will push up demand for meat from other major suppliers like the United States and Spain, boosting global prices.
CAIRO (Reuters) - Libyan commander Khalifa Haftar has committed to ending a months-long blockade of oil facilities, the U.S.